Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRENASDAQ:CYCNNASDAQ:LPTXNASDAQ:MBRXNASDAQ:ZSAN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$1.75+2.9%$1.73$1.41▼$5.01$9.68M1.1926,144 shs9,119 shsCYCNCyclerion Therapeutics$3.31+0.2%$3.12$1.27▼$9.47$10.61M1.551.28 million shs19,378 shsLPTXLeap Therapeutics$0.29$0.37$0.22▼$4.79$11.94M-0.281.09 million shs292,332 shsMBRXMoleculin Biotech$0.35+0.7%$0.77$0.25▼$4.71$4.95M1.381.92 million shs1.26 million shsZSANZosano Pharma$0.00$3.90$0.46▼$37.45$1K3.3425,375 shs5,685 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics+2.94%-0.14%-3.53%+2.94%-54.78%CYCNCyclerion Therapeutics+0.15%+17.62%+3.28%+32.20%+46.89%LPTXLeap Therapeutics0.00%+2.97%-22.27%+8.43%-84.26%MBRXMoleculin Biotech+0.72%+8.70%-58.34%-57.32%-90.36%ZSANZosano Pharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPREAprea Therapeutics2.8664 of 5 stars3.54.00.00.01.10.81.3CYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALPTXLeap Therapeutics1.4549 of 5 stars3.02.00.00.00.60.01.3MBRXMoleculin Biotech2.9519 of 5 stars3.52.00.00.02.51.71.3ZSANZosano PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 3.00Buy$15.50785.71% UpsideCYCNCyclerion Therapeutics 0.00N/AN/AN/ALPTXLeap Therapeutics 2.00Hold$3.381,071.88% UpsideMBRXMoleculin Biotech 3.00Buy$4.001,042.86% UpsideZSANZosano Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ZSAN, LPTX, APRE, MBRX, and CYCN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025APREAprea TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.006/18/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/9/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$4.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$1.50M6.45N/AN/A$3.55 per share0.49CYCNCyclerion Therapeutics$2M5.30N/AN/A$3.27 per share1.01LPTXLeap TherapeuticsN/AN/AN/AN/A$0.91 per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$1.77 per shareN/AZSANZosano Pharma$790K0.00N/AN/A$9.74 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.96M-$2.37N/AN/AN/A-1,095.02%-68.39%-55.74%8/11/2025 (Estimated)CYCNCyclerion Therapeutics-$3.06M-$1.16N/A∞N/AN/A-34.02%-30.68%8/6/2025 (Estimated)LPTXLeap Therapeutics-$67.56M-$1.70N/AN/AN/AN/A-162.15%-120.05%8/11/2025 (Estimated)MBRXMoleculin Biotech-$21.76MN/A0.00N/AN/AN/A-278.80%-100.11%8/4/2025 (Estimated)ZSANZosano Pharma-$29.92M-$14.50N/A∞N/A-8,375.11%-177.06%-119.14%N/ALatest ZSAN, LPTX, APRE, MBRX, and CYCN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025APREAprea Therapeutics-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million5/13/2025Q1 2025LPTXLeap Therapeutics-$0.38-$0.37+$0.01-$0.37N/AN/A5/13/2025Q1 2025MBRXMoleculin Biotech-$0.71-$0.69+$0.02-$0.69N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/AZSANZosano PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.905.90CYCNCyclerion TherapeuticsN/A4.214.21LPTXLeap TherapeuticsN/A2.412.41MBRXMoleculin BiotechN/A1.351.35ZSANZosano PharmaN/A1.611.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%CYCNCyclerion Therapeutics75.62%LPTXLeap Therapeutics30.46%MBRXMoleculin Biotech15.52%ZSANZosano PharmaN/AInsider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics13.63%CYCNCyclerion Therapeutics34.30%LPTXLeap Therapeutics7.50%MBRXMoleculin Biotech1.90%ZSANZosano Pharma2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics75.53 million4.78 millionNo DataCYCNCyclerion Therapeutics303.21 million2.11 millionNo DataLPTXLeap Therapeutics4041.44 million38.33 millionOptionableMBRXMoleculin Biotech2014.13 million13.86 millionNot OptionableZSANZosano Pharma404.90 million4.78 millionNot OptionableZSAN, LPTX, APRE, MBRX, and CYCN HeadlinesRecent News About These CompaniesMicroneedles for Drug Delivery Patent Landscape Report and Forecast 2024-2032, Featuring Minnesota Mining and Manufacturing, BD and Co, Zosano Pharma, Raphas, Nano, and Pass TechnologiesMarch 7, 2025 | globenewswire.comNifty PharmaAugust 2, 2024 | economictimes.indiatimes.comThe seven steps to selling in pharmaJuly 31, 2024 | pharmaphorum.comPAktuelle Empfehlungen zur ZOSANOJuly 28, 2024 | finanznachrichten.deHOOK HOOKIPA Pharma Inc.April 12, 2024 | seekingalpha.comNachrichten - Weitere NachrichtenJanuary 9, 2024 | wallstreet-online.deWLISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy planDecember 6, 2023 | pbs.orgPDer Börsen-Tag: Diese US-Aktie stürzte nachbörslich abAugust 22, 2023 | n-tv.deNEast Bay Business NewsMay 18, 2023 | bizjournals.comMankind Pharma IPO opens on April 25, listing scheduled for May 9April 27, 2023 | moneycontrol.comAstellas PharmaApril 6, 2023 | forbes.comGiiant Pharma Receives Financial Support From the US Crohn’s and Colitis FoundationFebruary 5, 2023 | finance.yahoo.comFTC asks court to hold 'pharma bro' Martin Shkreli in contempt for failing to abide by ordersJanuary 23, 2023 | washingtonexaminer.comWZosano Pharma Corporation (ZSANQ)November 5, 2022 | ca.finance.yahoo.comNow bankrupt, Zosano sells off its drug delivery tech that once enticed Novo Nordisk, Eli LillyOctober 13, 2022 | endpts.comEBankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma GiantsOctober 12, 2022 | msn.comBankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of ClaimsAugust 28, 2022 | marketwatch.comEast Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 millionAugust 27, 2022 | bizjournals.comZosano Pharma Corp (ZSANQ)August 24, 2022 | investing.comEast Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1MJuly 26, 2022 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZSAN, LPTX, APRE, MBRX, and CYCN Company DescriptionsAprea Therapeutics NASDAQ:APRE$1.75 +0.05 (+2.94%) Closing price 07/3/2025 01:56 PM EasternExtended Trading$1.75 0.00 (0.00%) As of 07/3/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Cyclerion Therapeutics NASDAQ:CYCN$3.30 +0.01 (+0.15%) As of 07/3/2025 02:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Leap Therapeutics NASDAQ:LPTX$0.29 0.00 (0.00%) Closing price 07/3/2025 03:13 PM EasternExtended Trading$0.29 0.00 (0.00%) As of 07/3/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Moleculin Biotech NASDAQ:MBRX$0.35 +0.00 (+0.72%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$0.35 0.00 (0.00%) As of 07/3/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.Zosano Pharma NASDAQ:ZSANZosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
